Proteome Says Study Using SysQuant Technology Demonstrates Its Potential

LONDON (Alliance News) - Proteome Sciences PLC said Thursday that a study using its SysQuant technology to address pancreatic cancer published in medical journal PLOS ONE demonstrated the potential of proteomics to improve the way that bespoke treatments can be made to match patients.

Proteomics is the large-scale study of proteins.

The technology was used to map switches regulating cell signalling pathways in patient samples. This analysis is then used to predict the likelihood of recurrence of tumours and mechanises that could be used to elude anti-cancer therapies. This allows doctors to focus on the right resources for each patient.

"This study is the first peer-reviewed article on SysQuant that shows a truly comprehensive analysis of cell signalling pathway mapping in pancreatic," said Chief Operating Officer Ian Pike in a statement.

The company said that the SysQuant can be used to analyse tissues across a range of different therapeutic areas.

Shares in Proteome Sciences were trading up 1.45% at 35.00 pence Thursday.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright © 2014 Alliance News Limited. All Rights Reserved.

Proteome